



Q1 FY27 QUARTERLY COMPANY CALL

21 October 2026

DISCLAIMER

Introduction

THIS PRESENTATION IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO OR FROM THE UNITED STATES OF AMERICA OR TO ANY RESIDENT THEREOF, OR ANY OTHER JURISDICTION WHERE SUCH RELEASE, PUBLICATION OR DISTRIBUTION IS UNLAWFUL. THIS DOCUMENT IS NOT, AND DOES NOT CONSTITUTE, AN OFFER OR INVITATION TO SUBSCRIBE FOR, BUY OR SELL SECURITIES IN ANY JURISDICTION. BY ACCEPTING, ACCESSING OR REVIEWING THIS PRESENTATION, YOU ACKNOWLEDGE AND AGREE TO THE TERMS SET OUT BELOW.

This presentation has been prepared by CurveBeam AI Limited (ACN 140 706 618) (**CurveBeam** or the **Company**) and contains summary information about CurveBeam and the business conducted by it as at 20th Oct 2026. The information in this presentation is for informational purposes only, does not purport to be complete and is not a prospectus, product disclosure statement or other offering document for the purposes of Chapter 6D or Part 7.9 of the Corporations Act 2001 (Cth) (**Act**) or the law of any other jurisdiction. It should be read in conjunction with CurveBeam's other periodic and continuous disclosure announcements, including its full year results for the period ended 30 June 2025, and half year results for the period ended December 31st 2025, lodged with the ASX on 28 August 2025 and 28 February 2026, available from the Australian Securities Exchange ("ASX") at www.asx.com.au.

As further detailed below, none of CurveBeam, nor its advisers (**Advisers**) nor their respective affiliates, related bodies corporate (as defined in the Act) or security holders and their respective directors, officers, employees, partners, representatives, consultants, agents or advisers (each a **Limited Party** and together, the **Limited Parties**) guarantees, recommends, or makes any representation or warranty to, or takes responsibility for, the accuracy, reliability or completeness of the information contained in this presentation or the Company's securities, including, without limitation, any liability arising from fault or negligence, for any loss arising from the use of or reliance on any of the information contained in this presentation or otherwise arising in connection with it. To the maximum extent permitted by law, each Limited Party disclaims any liability for any loss arising from the use of or reliance on such information including as to the accuracy or completeness of the information, statements, opinions or matters, express or implied, contained in, arising out of or derived from, or for omissions from, this presentation.

Not an offer or financial product advice

The information contained in this presentation is for informational purposes only and should not be considered, and does not contain or purport to contain, an offer, invitation, solicitation or recommendation with respect to the subscription, purchase or sale of any securities in CurveBeam nor does it constitute legal, taxation, financial product or investment advice. The general information in this presentation has been prepared without taking into account the investment objectives, financial situation or particular needs of any particular person. Recipients of the presentation must undertake their own independent investigations, consideration and evaluation. Neither this presentation nor any of its contents will form the basis of any contract or commitment and it is not intended to induce or solicit any person to engage in any transaction nor is it intended to be used as the basis for making an investment decision. CurveBeam recommends that potential investors consult their professional advisors as an investment in CurveBeam is subject to investment and other known and unknown risks, some of which are beyond the control of CurveBeam or its directors and therefore any investment is considered to be speculative in nature.

Forward looking statements

The information given in this presentation is given for illustrative purposes only and should not be relied upon as (and is not) an indication of CurveBeam's views on future performance or condition. Past performance cannot be relied upon as an indicator of future performance. This presentation contains certain forward-looking statements. The words "forecast", "estimate", "like", "anticipate", "opinion", "should", "could", "may" and other similar expressions are intended to identify future earnings, financial position and performance of CurveBeam. You are cautioned not to place undue reliance on these statements. These forward-looking statements are based on estimates, projections and assumptions made by CurveBeam about circumstances and events that have not yet taken place. Although due care and attention has been used in the preparation of these statements, such forward-looking statements are based on numerous assumptions regarding CurveBeam's present and future business strategies and the political, regulatory and economic environment in which CurveBeam will operate in the future and are subject to change without notice. Statements about market and industry trends, which are based on interpretations of current market conditions, may not be reasonable, and are not guarantees or predictions of future performance.

The actual results or performance of CurveBeam may be materially different from the results or performance expressed or implied by such forward-looking statements. No representation, warranty or assurance (express or implied) is given or made in relation to any forward-looking statement by any person (including any of the Limited Parties). No representation, warranty or assurance (express or implied) is given that the occurrence of the events expressed or implied in any forward-looking statement in this presentation will actually occur. Subject to any continuing obligations under applicable law, the Company expressly disclaims any obligation or undertaking to provide any updates or revisions to any forward-looking statements in this presentation to reflect any change in expectations in relation to any forward-looking statement or any change in events, conditions or circumstances on which any statement is based.


The distribution of this Presentation in jurisdictions outside Australia may be restricted by law and you should observe any such restrictions. Any failure to comply with such restrictions may constitute a violation of applicable securities laws. In particular, this Presentation may not be distributed or released in the United States. The entitlements and the New Shares have not been, and will not be, registered under the U.S. Securities Act of 1933, as amended ("**U.S. Securities Act**"), or the securities laws of any state or other jurisdiction of the United States, and may not be offered or sold, directly or indirectly, in the United States, unless they have been registered under the U.S. Securities Act (which CurveBeam has no obligation to do or procure) or are offered or sold in a transaction exempt from, or not subject to, the registration requirements of the U.S. Securities Act and any other applicable U.S. state securities laws. Refer to the Appendix of this Presentation for further details about international offer restrictions.

Financial information

All numbers in this presentation are stated in Australian dollars (**A\$**) unless stated otherwise.

Q1 FY27 KEY HIGHLIGHTS


- Purchase orders (POs) secured during Q1 FY27 **totaled five (5)** devices, all HiRise™ marking the strongest Q1 sales result to date
- Company received U.S. **FDA 510(k) clearance** for Bone Mineral Density (**BMD**) for multidetector CT (MDCT)
- Following successful responses to the NMPA's second round of feedback, HiRise™ received **regulatory clearance in China** on 12 October 2026. This milestone triggers a A\$1.0 million payment
- We expect this will pave the way for Weiyang/WEGO's initial order of U.S.-manufactured HiRise™ systems for distribution in China
- A **further A\$3.0 million in milestone payments** is payable in relation to sales of HiRise in China, comprising A\$1.0 million upon the sale of the first 10 systems and A\$2.0 million upon the sale of the first 50 systems, in addition to revenue from product sales



HiRise™

Q1 FY27 KEY HIGHLIGHTS

- The Company continues to advance the validation pathway for HiRise™ datasets with a **major robotic-assisted surgery system**
- Latest trial scans have demonstrated that HiRise™ data could be **processed successfully** through applicable software workflows, with motion failure rates below acceptable thresholds, positively progressing formal validation for total knee replacement.
- Similar trials for total hip replacement will follow, under appropriate regulatory and clinical governance requirements
- The Company is **continuing to progress collaboration with other robotic surgery platforms** & has expanded its validation activities from total knee arthroplasty to include total hip arthroplasty. This helps to facilitate expansion of potential addressable market for HiRise™ within robotic orthopaedic surgery domain



HiRise™


Q1 FY27 CASH ANALYSIS

- Company **raised a total of A\$7.35 m** through a combination of capital raisings, comprising a A\$5.0 m placement (A\$0.02/share), an SPP raising of A\$0.6 m (A\$0.018/share), and a Shortfall Offer and placement raising of an additional A\$1.75 m (A\$0.018/share)
- During the quarter, we implemented operating expense reductions, including staff & savings across other Operating Expenses (OpEx), reducing annualised cash related **OpEx to approximately \$15 m**
- Quarter closed with a **cash balance of A\$5.83m**, with 4.3 quarters of cash available as disclosed at item 8.5 of the Appendix 4C
- Cashflows used in operations for Q1 was (A\$1.36m) versus cash used in operations of (A\$2.42m) in Q4 FY26, a **reduction of 44%**



HiRise™

Q1 FY27 PURCHASE ORDERS ANALYSIS




- Receipts Q1 FY27 were A\$1.80m, down 30% from A\$2.58m in Q4 FY26, up 31% from comparative quarter in FY26 A\$1.37m
- CVB carried A\$4.2m of purchase orders & receivables into Q1 & carries A\$4.9m into Q2. Revenue recognition cycle of CVB ranges from 2-to-6 months from PO to installation to receipt



BONEVUE BMD MDCT FDA CLEARED


Multidetector CT (MDCT)



2nd Step
clearance





HiRise



DXA – dual
energy scanner

- September, CurveBeam AI received U.S. FDA (FDA) 510(k) clearance for its first product for CT-based Bone Mineral Density (BMD) for multidetector CT (MDCT) scans.
- Following feedback from the FDA during the 510(k) review process, the Company will now move to complete validation of automated region-of-interest selection functionality, & reporting of T & Z scores for MDCT
- The strategy remains to leverage this initial MDCT FDA clearance as the foundation for a second regulatory submission to expand the BMD capability onto the HiRise™ platform
- This planned Special 510(k) will be supported by data collection currently being scoped & budgeted. MDCT BMD module provides CVB with an opportunity to address the unmet need for rapid bone quality assessment in the elderly within joint replacement & acute care settings


ENHANCED HIRISE™ PROJECT FOR ROBOTIC AIDED SURGICAL SYSTEMS



- CurveBeam AI has now implemented significant product improvements, including enhanced patient stabilisation methods & software-based anatomical alignment refinements designed to meet the clinical and technical objectives for surgical system workflows
- During the quarter, the Company continued to collaborate with a leading robotic surgery platform with HiRise™ scan processing, to advance the pathway for HiRise™ compatibility with its solutions
- This should lead to formal validation of HiRise data for its total knee replacement. The company is also extending this project for total hip replacement, with both pathways being under appropriate regulatory & clinical governance requirements

ROBOTIC MARKET DYNAMICS – DRIVES CT DEPENDENCE

1. Robotic system adoption for orthopedics continues at a steady pace with ~ 25% of US operating rooms having access to a robot - Source Global Data 2023
2. Stryker MAKO, J&J VELYS, Zimmer ROSA and S&N CORI – held 85% of the market - Source Global Data 2023
3. MAKO is the only system of the top four to use CT scans for 3D pre-operative planning
4. Stryker has the dominant position with 3000 placements globally. US Estimate for MAKO placements 2000 <https://www.borderless.net/news/life-sciences/stryker-starts-limited-release-of-mako-rps-handheld-knee-robot>



DEFINITIONS

CurveBeam AI's key metrics are defined and interpreted as follows:

- **Purchase order** – a signed purchase order (PO) for a CT scanner (device). The Company considers POs to be a key metric as it reflects actual sales at any given time.
- **Receipts from customers** – any cash consideration received from a customer by CurveBeam AI. This can include initial deposits required at the time of an order being placed.
- **Revenue** – Revenue is recognised after the device (e.g., HiRise™) is delivered, installed and training has been completed. Depending on the customer site requirements, there can be several months' delay from a signed purchase order to recognition of revenue. Thus, revenue may not be reflective of sales progress in each period.

The Company will report on POs and cash receipts in its Appendix 4C (quarterly) lodgments, while revenue will be reported in Appendix 4E (full year report) and Appendix 4D (half year report).

QUESTIONS

